Jonathan Jay Mazelsky Sells 23,326 Shares of IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) CEO Jonathan Jay Mazelsky sold 23,326 shares of the business’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the transaction, the chief executive officer owned 83,606 shares in the company, valued at $54,975,125.30. The trade was a 21.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

IDEXX Laboratories Trading Down 0.2%

IDXX opened at $635.54 on Wednesday. The firm has a market capitalization of $50.60 billion, a price-to-earnings ratio of 48.63, a price-to-earnings-growth ratio of 3.87 and a beta of 1.66. The company’s 50 day simple moving average is $670.70 and its two-hundred day simple moving average is $668.89. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the company earned $2.53 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of recent analyst reports. Barclays decreased their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday. Jefferies Financial Group reaffirmed a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Finally, Morgan Stanley upped their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $783.33.

Hedge Funds Weigh In On IDEXX Laboratories

Several institutional investors have recently modified their holdings of IDXX. Reflection Asset Management purchased a new position in IDEXX Laboratories in the fourth quarter worth approximately $53,000. BDFS Capital LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth $671,000. MidFirst Bank acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth $2,960,000. Pacer Advisors Inc. increased its holdings in IDEXX Laboratories by 10.0% in the fourth quarter. Pacer Advisors Inc. now owns 13,965 shares of the company’s stock valued at $9,448,000 after buying an additional 1,269 shares during the last quarter. Finally, Titan Investment Management LLC acquired a new stake in IDEXX Laboratories in the fourth quarter valued at $1,675,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.